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Background
An early event in Alzheimer’s Disease (AD) is synaptic
failure, making the disease fundamentally a disorder of
impaired cognition and memory. Synaptic plasticity
requires activation of gene expression programs with
dysfunction of the transcription factor cAMP-response
element binding protein (CREB) strongly implicated in
AD etiology.
Results and Conclusion
The hypothesis that activation of CREB through NO/
cGMP signaling might modify the amyloid-b (Ab) neu-
ropathology, linked to AD pathogenesis, was demon-
strated in both APP/PS1 and 3xTg transgenic mouse
models of AD using small molecules, termed nomethia-
zoles, also designed to provide neuroprotection and
attenuate pro-inflammatory cytokine release. Functional
restoration of long-term potentiation was shown in hip-
pocampal slices from AD transgenic mice in accord
with observation of restoration of cognitive function in
vivo, and was dependent upon soluble guanylyl cyclase
(sGC) activation. Levels of pCREB and BDNF were sig-
nificantly elevated, whereas TNFa, Ab, oligomeric Ab1-
42, and also tau protein were significantly lowered after
drug treatment. In the absence of neuronal loss in ani-
mal models of AD, neuroprotection was demonstrated
in rat primary neurons after oxygen-glucose deprivation
or application of oligomeric Ab. The lead nomethiazole
was also studied in a novel transgenic mouse model,
E4FAD, which incorporates familial AD mutations, but
also has targeted replacement of mouse apolipoprotein-
E with human ApoE4, the major genetic risk factor for
sporadic and age-related AD.
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